Open AccessThe use of low molecular weight heparins in patients with acute ST-elevated myocardial infarction
Author(s) -
Milovan Petrović,
Gordana Panić,
Tibor Čanji,
Ilija Srdanović,
Vladimir Ivanović,
D Benc
Publication year - 2006
Publication title -
medicinski pregled
Language(s) - English
Resource type - Journals
eISSN - 1820-7383
pISSN - 0025-8105
DOI - 10.2298/mpns0610476p
Subject(s) - medicine , cardiogenic shock , myocardial infarction , timi , streptokinase , low molecular weight heparin , heparin , cardiology , revascularization , adverse effect , anticoagulant , surgery , thrombolysis
According to the published guidelines for the management of acute coronary syndromes (ACS), treatment of acute ST-elevated myocardial infarction is based on rapid revascularization, either mechanical or pharmacological. Pharmacological revascularization consists of fibrinolytic therapy with antiplatelet and anticoagulant therapy. In regard to the anticoagulant therapy, low molecular weight heparins (LMWHs) are of special importance. LMWHs cause less complications (bleeding, thrombocytopenia, better bioviability) in comparison with unfractionated heparin (UFH). Some studies on use of LMWHs in ACS, show that LMWHs are equally efficient and safe as UFH, causing less complications (different types of hemorrhagic complications) (ESSENCE, TIMI 11B (enoxaparin), FRAXIS-fraxiparin), whereas some studies show better efficacy and safety of enoxaparin in therapy of acute ST-elevated myocardial infarction (ASSENT 3, ASSENT 3 PLUS, HART II, AMI-SK).